Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.36 |
| ▸ | CCR1 | P32246 | 2/20 | 0.33 |
| ▸ | CCR5 | P51681 | 2/20 | 0.33 |
| ▸ | CCR8 | P51685 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.33 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1450435 | 0.85 | CYP1A2 (0.53) | CYP1A2CYP2A6UHRF1CCR1CCR5 | |
| SCHEMBL4023171 | 0.77 | KDM4E (0.30) | KDM4E | |
| SCHEMBL5658397 | 0.77 | KDM4E (0.43) | CYP2A6KDM4E | |
| SCHEMBL756551 | 0.71 | CYP2A6 (0.32) | CYP2A6 | |
| SCHEMBL9169786 | 0.71 | CYP2A6 (0.34) | CYP1A2CYP2A6CCR1CCR8 | |
| SCHEMBL29561259 | 0.70 | CYP1A2 (1.00) | CYP1A2CYP2A6UHRF1CCR1CCR5 | |
| SCHEMBL112229 | 0.70 | CYP1A2 (1.00) | CYP1A2CYP2A6UHRF1CCR1CCR5 | |
| SCHEMBL645977 | 0.69 | CYP2A6 (0.48) | CYP1A2CYP2A6KDM4E | |
| SCHEMBL1921671 | 0.69 | ALDH1A1 (0.32) | CYP2A6 | |
| SCHEMBL1260006 | 0.69 | LMNA (0.36) | CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0030198-B1 | ISOQUINOLINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC SANTE (FR) | 1983-03-02 | — | — | EP | claimed |
| US-4363909-A | ANTIVIRAL AGENTS | RHONE POULENC INDUSTRIES (FR) | 1982-12-14 | — | — | US | claimed |
| US-7285563-B2 | Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2007-10-23 | — | — | US | disclosed |
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2005-05-19 | — | — | US | disclosed |
| US-4363909-A | ANTIVIRAL AGENTS | RHONE POULENC INDUSTRIES (FR) | 1982-12-14 | — | — | US | disclosed |
| US-4363909-A | ANTIVIRAL AGENTS | RHONE POULENC INDUSTRIES (FR) | 1982-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | ARRB1, OPRL1, CNR1 | CYP1A2 464/4885CYP2A6 743/4885UHRF1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.